PMV Pharmaceuticals Q3 2026 Results: Net Loss of $34.4M, Loss Widens
PMV Pharmaceuticals reported a significant increase in total liabilities to $54.3 million as of September 30, 2026, primarily driven by a new $43.6 million warrant liability. The company's cash and marketable securities totaled approximately $108.5 million, while the accumulated deficit grew to $517.0 million.
- Key figure
- Net loss $34.4M